上海药明生物技术有限公司 Wuxi Biologics Mediaroom

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2026-03-30 13:33 4246

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2026-03-25 18:22 4394

WuXi Biologics Reports Record 2025 Annual Results

* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew ov...

2026-03-24 19:44 3327

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffir...

2026-03-22 09:30 3183

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...

2026-03-13 11:09 4193

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-03-02 11:21 5346

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Researc...

2026-02-03 11:22 8511

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-29 10:39 8725

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Researc...

2026-01-26 17:35 15524

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 comme...

2026-01-15 12:00 7614

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...

2026-01-13 11:07 8691

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...

2026-01-13 11:07 5963

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-12 21:09 5978

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20...

2026-01-05 11:57 4637

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security

SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named t...

2025-12-19 17:30 5119

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

* The only company from pharmaceutical industry selected for inclusion in the Index * Also incl...

2025-10-22 08:30 2992

WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research...

2025-10-10 08:30 1663

WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability

* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integratio...

2025-09-25 19:42 2145

WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year

SHANGHAI, Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Resear...

2025-09-23 12:00 3623

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)

WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Res...

2025-09-17 12:00 2257

Latest News